Product Description
TIA-1 Antibody [TRIA1-1] | 34-055 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human partial recombinant protein (amino acids 279-380) was used as the immunogen for this TIA-1 antibody.
Research Area: Cancer, Apoptosis
Tested Application: WB, Flow, IF
Application: Flow Cytometry: 0.5-1ug/10^6 cells
IF: 1-2 ug/ml
Western blot: 1-2 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the TIA-1 antibody to be titered up or down for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: TRIA1-1
Isotype: IgG2b
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: TIA1, WDM, TIA-1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: T-Cell Intracellular Antigen-1 is a cytoplasmic granule-associated protein expressed in lymphocytes processing cytolytic potential. It is a member of an RNA-binding protein family and possesses nucleolytic activity against cytotoxic lymphocyte (CTL) target cells. It has been suggested that this protein may be involved in the induction of apoptosis as it preferentially recognizes poly (A) homopolymers and induces DNA fragmentation in CTL targets. The major granule-associated species is a 15kDa protein thought to be derived from the carboxyl terminus of the 40kDa product by proteolytic processing. TIA-1 antibody labels cytotoxic T cells and natural killer cells (NK cells) . It is also expressed in T-cell lymphoma, large granular lymphocyte (LGL) leukemia and hairy cell leukemia. TIA1 expression in T-cell malignancies may help in differentiating LGL leukemia (high expression) from T-cell lymphocytosis and other T-cell diseases (low expression) . TIA1 may also be used to label tumor-infiltrating lymphocytes in the study of immune response to malignancies.